These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 17058770)

  • 1. [A blood transfusion in Sweden--the societal cost].
    Glenngård AH; Persson U
    Lakartidningen; 2006 Sep 20-26; 103(38):2752-6. PubMed ID: 17058770
    [No Abstract]   [Full Text] [Related]  

  • 2. Costs associated with blood transfusions in Sweden--the societal cost of autologous, allogeneic and perioperative RBC transfusion.
    Glenngård AH; Persson U; Söderman C
    Transfus Med; 2005 Aug; 15(4):295-306. PubMed ID: 16101807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regarding the article "costs associated with blood transfusion in Sweden - the societal cost of autologous, allogeneic and perioperative RBC transfusion".
    Jidell E; Norda R; Berseus O; Swärd-Nilsson AM
    Transfus Med; 2006 Apr; 16(2):151-2; author reply 153. PubMed ID: 16623922
    [No Abstract]   [Full Text] [Related]  

  • 4. [Autologous blood transfusion is preferable in orthopedic surgery].
    Fredin H; Elawad AA; Benoni G
    Lakartidningen; 1992 Feb; 89(9):637-8, 643-4. PubMed ID: 1538616
    [No Abstract]   [Full Text] [Related]  

  • 5. [Autologous blood donation versus homologous blood transfusion--an analysis of cost effectiveness].
    Dietrich GV
    Zentralbl Chir; 1996; 121(10):841-6. PubMed ID: 9019932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the cost of autologous erythrocyte concentrates in a hospital].
    Gouëzec H; Tardivel R; Danic B; Ballay JL; Malledant Y
    Cah Anesthesiol; 1996; 44(5):451-4. PubMed ID: 9183429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada.
    Amin M; Fergusson D; Wilson K; Tinmouth A; Aziz A; Coyle D; Hébert P
    Transfusion; 2004 Oct; 44(10):1479-86. PubMed ID: 15383022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The implications of cost-effectiveness for autologous blood procurement.
    Adegboyega PA
    Arch Pathol Lab Med; 1994 Dec; 118(12):1168-9. PubMed ID: 7979905
    [No Abstract]   [Full Text] [Related]  

  • 9. [On the analysis of the cost-effectiveness ratio for autologous transfusion programs].
    Moral García V; Díaz Espallardo C
    Rev Esp Anestesiol Reanim; 2001 May; 48(5):249-50. PubMed ID: 11412738
    [No Abstract]   [Full Text] [Related]  

  • 10. Postoperative salvage: a technological advance in the 'washed' versus 'unwashed' blood controversy.
    Tawes RL; Sydorak GR; DuVall TB
    Semin Vasc Surg; 1994 Jun; 7(2):98-103. PubMed ID: 8087291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of recombinant erythropoietin in surgery--are the costs justified?].
    Wolff M; Fandrey J; Jelkmann W; Hirner A
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():143-5. PubMed ID: 9101815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical study on the feasibility of autologous cord blood transfusion for anemia of prematurity.
    Khodabux CM; von Lindern JS; van Hilten JA; Scherjon S; Walther FJ; Brand A
    Transfusion; 2008 Aug; 48(8):1634-43. PubMed ID: 18507748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An economic analysis of costs associated with development of a cell salvage program.
    Waters JR; Meier HH; Waters JH
    Anesth Analg; 2007 Apr; 104(4):869-75. PubMed ID: 17377098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of the cost effectiveness ratio of an autotransfusion program for primary prosthetic knee and hip surgery].
    Muñoz Gómez M; García-Vallejo JJ; Clavero Barranquero A; López-Andrade Jurado A; Ruiz Romero de la Cruz MD
    Rev Esp Anestesiol Reanim; 2001 Jan; 48(1):43-4. PubMed ID: 11234608
    [No Abstract]   [Full Text] [Related]  

  • 15. Perioperative blood salvage.
    no author
    Vox Sang; 2006 Aug; 91(2):185-92. PubMed ID: 16907883
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of cell salvage in routine cardiac surgery is ineffective and not cost-effective and should be reserved for selected cases.
    Attaran S; McIlroy D; Fabri BM; Pullan MD
    Interact Cardiovasc Thorac Surg; 2011 May; 12(5):824-6. PubMed ID: 21297148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transfusion of autologous bone marrow for the prevention and treatment of postoperative anemia].
    Malakhov SF; Men'shikova EA; Shelukhin VA; Bagautdinov ShM
    Vestn Khir Im I I Grek; 1982 Dec; 129(12):93-7. PubMed ID: 6762753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reasons against the retransfusion of unwashed wound blood.
    Hansen E; Hansen MP
    Transfusion; 2004 Dec; 44(12 Suppl):45S-53S. PubMed ID: 15585005
    [No Abstract]   [Full Text] [Related]  

  • 19. [Autologous blood pre-donation and perioperative use of erythropoietin].
    Michaeli B; Ravussin P; Chassot PG
    Rev Med Suisse; 2006 Nov; 2(88):2662-4, 2666-7. PubMed ID: 17265804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.
    Borg S; Glenngård AH; Osterborg A; Persson U
    Acta Oncol; 2008; 47(6):1009-17. PubMed ID: 18770060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.